Chemomab Therapeutics Ltd
CMMB1.009USD
-0.021-2.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
19.04MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Chemomab Therapeutics Ltd Unternehmen
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Unternehmensinformationen
BörsenkürzelCMMB
Name des UnternehmensChemomab Therapeutics Ltd
IPO-datumAug 14, 2012
CEODr. Adi Mor, Ph.D.
Anzahl der mitarbeiter16
WertpapierartDepository Receipt
GeschäftsjahresendeAug 14
AddresseKiryat Atidim, Building 7
StadtTEL AVIV-YAFO
BörseNASDAQ Capital Market Consolidated
LandIsrael
Postleitzahl6158002
Telefon972773310156
Websitehttps://www.chemomab.com/
BörsenkürzelCMMB
IPO-datumAug 14, 2012
CEODr. Adi Mor, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
2.56K
-82.97%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.20K
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
2.56K
-82.97%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.20K
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 19
Aktualisiert: Sat, Jul 19
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Otto (Erik)
6.03%
Apeiron Investment Group Ltd
5.91%
Rivendell Investments 2017-9 LLC
5.78%
Sphera Funds Management Ltd.
4.70%
Yelin Lapidot Provident Funds Management Ltd
3.02%
Other
74.57%
Aktionäre
Aktionäre
Anteil
Otto (Erik)
6.03%
Apeiron Investment Group Ltd
5.91%
Rivendell Investments 2017-9 LLC
5.78%
Sphera Funds Management Ltd.
4.70%
Yelin Lapidot Provident Funds Management Ltd
3.02%
Other
74.57%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
9.48%
Hedge Fund
5.93%
Family Office
5.91%
Corporation
5.78%
Investment Advisor
3.31%
Research Firm
0.83%
Private Equity
0.69%
Investment Advisor/Hedge Fund
0.20%
Venture Capital
0.07%
Other
67.80%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
36
5.04M
26.29%
-1.09M
2025Q1
38
6.66M
34.89%
+231.83K
2024Q4
41
7.89M
41.83%
+519.06K
2024Q3
37
7.12M
38.75%
+430.17K
2024Q2
36
5.24M
33.24%
-261.90K
2024Q1
39
5.24M
33.39%
-405.62K
2023Q4
41
5.39M
34.50%
+2.72K
2023Q3
43
5.63M
49.23%
-777.20K
2023Q2
42
5.63M
49.23%
-912.41K
2023Q1
44
6.00M
54.09%
-854.86K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Otto (Erik)
1.16M
6.03%
+1.16M
--
Nov 21, 2024
Apeiron Investment Group Ltd
1.13M
5.91%
+404.86K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
1.11M
5.78%
--
--
Dec 31, 2024
Sphera Funds Management Ltd.
900.43K
4.7%
-314.15K
-25.86%
Mar 31, 2025
Yelin Lapidot Provident Funds Management Ltd
578.29K
3.02%
-165.84K
-22.29%
Mar 31, 2025
Mor George (Adi)
317.07K
1.65%
--
--
Dec 31, 2024
Ikarian Capital LLC
213.05K
1.11%
--
--
Mar 31, 2025
George (Kobi)
200.24K
1.04%
-50.91K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
141.22K
0.74%
-10.00K
-6.61%
Dec 31, 2024
OrbiMed Advisors, LLC
131.27K
0.69%
-1.61M
-92.46%
Jun 23, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Datum
Art
Verhältnis
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
Mar 16, 2021
Merger
16<1
